Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…Abstract Number: 1925 • ACR Convergence 2021
Risk of Heart Failure in Patients with Inflammatory Disease: A Population-Based Study
Background/Purpose: Individuals with inflammatory diseases (ID) have an increased risk of cardiovascular disease, frequently compared to that of diabetes mellitus (DM). However, the magnitude of…Abstract Number: 0066 • ACR Convergence 2021
Characterization of αβTCR of HLA-B*27-Restricted CD8 T-Cell Clones Associated with Spondyloarthropathies
Background/Purpose: The mechanism by which HLA-B27 induces Ankylosing Spondylitis (AS) and related disease is unknown, but a leading hypothesis is that it presents ‘arthritogenic epitopes’…Abstract Number: 0372 • ACR Convergence 2021
Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…Abstract Number: 0918 • ACR Convergence 2021
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is effective in patients with radiographic axial spondyloarthritis (rad-axSpA). Assessment in SpondyloArthritis International Society (ASAS) 40 response – the…Abstract Number: 1305 • ACR Convergence 2021
Undiagnosed Depression in Axial Spondyloarthropathy and the Negative Impact on Patient Outcomes: Results of a Screening Study
Background/Purpose: Previous research in axial spondyloarthropathy(axSpA) has shown this population to have a high prevalence of depression. This co-morbidity has been previously shown to impact…Abstract Number: 0067 • ACR Convergence 2021
Mendelian Randomisation Analysis of Protein Quantitative Trait Loci with Ankylosing Spondylitis Reveals Causative Involvement of Key Effector Proteins and Pathways
Background/Purpose: Susceptibility to ankylosing spondylitis (AS) is known to be highly influenced by genetic factors, with heritability assessed in twins of >90%, with >115 genetic…Abstract Number: 0374 • ACR Convergence 2021
Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study
Background/Purpose: According to international recommendations, the Ankylosing Spondylitis Disease Activity Score (ASDAS) is the preferred score for assessing disease activity in axial spondyloarthritis (axSpA) [1].…Abstract Number: 0838 • ACR Convergence 2021
Predictors of Treatment for Inflammatory Arthritis with Immune Modulating Medications (IMM) in US Veterans
Background/Purpose: Non-treatment and treatment delays contribute to suboptimal symptom control and irreversible joint damage in patients with inflammatory arthritis (IA). This investigations objective was to…Abstract Number: 0919 • ACR Convergence 2021
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
Background/Purpose: Ixekizumab (IXE) demonstrated rapid efficacy in patients (pts) with AS at week (W) 16 in the absence of elevated inflammation as measured by baseline…Abstract Number: 1306 • ACR Convergence 2021
Clinical and Imaging Characteristics of Spondyloarthritis Among Crohn’s Disease Patients
Background/Purpose: Inflammatory bowel disease (IBD) affects up to 1.3% of the population and is associated with musculoskeletal manifestations including spondyloarthritis (SpA). Axial SpA (axSpA) is…Abstract Number: 0068 • ACR Convergence 2021
Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Randomization Studies
Background/Purpose: There is strong evidence from animal models, human microbiome profiling studies, genetic analyses, and from the model of reactive arthritis, that AS is caused…Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 62
- Next Page »